4.8 Article

Cell-Specific Delivery of Diverse Cargos by Bacteriophage MS2 Virus-like Particles

期刊

ACS NANO
卷 5, 期 7, 页码 5729-5745

出版社

AMER CHEMICAL SOC
DOI: 10.1021/nn201397z

关键词

virus-like particles; multivalent peptide display; targeted drug delivery; cancer; nanoparticle; nanocarrier

资金

  1. NIH/Roadmap for Medical Research [PHS 2 PN2 EY016570B]
  2. NCI [U01CA151792-01]
  3. Air Force Office of Scientific Research [FA 9550-07-1-0054/9550-10-1-0054]
  4. U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering
  5. Sandia National Laboratories
  6. NIH [R01 GM42901]
  7. IGERT Fellowship [NSF DGE-0504276]
  8. NSF [DGE-0549500]
  9. NSF, University of New Mexico Center for Micro-engineered Materials [DMR-0649132]
  10. NCRR
  11. University of New Mexico Health Sciences Center
  12. University of New Mexico Cancer Center
  13. United States Department of Energy's National Nuclear Security Administration [DE-AC04-94AL85000]

向作者/读者索取更多资源

Virus-like particles (VLPs) of bacteriophage MS2 possess numerous features that make them well-suited for use in targeted delivery of therapeutic and Imaging agents. MS2 VLPs can be rapidly produced in large quantities using in vivo or in vitro synthesis techniques. Their capsids can be modified in precise locations via genetic insertion or chemical conjugation, facilitating the multivalent display of targeting ligands. MS2 VU's also self-assemble in the presence of nucleic adds to specifically encapsidate siRNA and RNA-modified cargos. Here we report the use of MS2 VLPs to selectively deliver nanoparticles, chemotherapeutic drugs, siRNA cocktails, and protein toxins to human hepatocellular carcinoma (HCC). MS2 VLPs modified with a peptide (SP94) that binds HCC exhibit a 10(4)-fold higher avidity for HCC than for hepatocytes, endothelial cells, monocytes, or lymphocytes and can deliver high concentrations of encapsidated cargo to the cytosol of HCC cells. SP94-targeted VLPs loaded with doxorubicin, cisplatin, and 5-fluorouracil selectively kill the HCC cell line, Hep3B, at drug concentrations <1 nM, while SP94-targeted VLPs that encapsidate a siRNA cocktail, which silences expression of cyclin family members, Induce growth arrest and apoptosis of Hep3B at siRNA concentrations <150 pM. Impressively, M52 VLPs, when loaded with ricin toxin A-chain (RTA) and modified to codisplay the SP94 targeting peptide and a histidine-rich fusogenic peptide (H5WYG) that promotes endosomal escape, kill virtually the entire population of Hep3B cells at an RTA concentration of 100 fM without affecting the viability of control cells. Our results demonstrate that M52 VLPs, because of their tolerance of multivalent peptide display and their ability to specifically encapsidate a variety of chemically disparate cargos, Induce selective cytotoxicity of cancer in vitro and represent a significant improvement in the characteristics of VLP-based delivery systems.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据